DSIP, delta sleep-inducing peptide, is a nonapeptide first isolated from rabbit blood in 1977 during electrically induced delta-wave sleep. Unlike Semax and Selank, it was studied mainly in Western Europe and has genuine blinded, placebo-controlled human trials from the 1980s and 1990s. Those trials did not demonstrate the clean, reproducible deep-sleep effect its name and modern marketing imply; the clearest finding across them is a modest drop in ACTH, not a sleep-architecture change. It has never been approved as a drug anywhere.
What it is
Delta sleep-inducing peptide, DSIP, is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first reported in 1977 from the blood of rabbits during electrically induced delta-wave sleep. Unlike Semax and Selank, DSIP was studied mainly in Western Europe (Italy, Germany, Switzerland) from the late 1970s through the 1990s, and unlike either of those two compounds it has genuine, published, blinded, placebo-controlled human trials. It has never been approved as a drug anywhere; its name describes the effect its 1970s discoverers proposed for it, not an established mechanism.
Potential benefits and research applications
Deep sleep induction, the effect the compound is named for and marketed on
DSIP was originally isolated for its proposed ability to induce delta-wave (deep) sleep when transferred between animals, and this remains the primary reason it is sought out today. No controlled human trial located for this entry measured sleep architecture (EEG delta activity) as an outcome, so the compound’s namesake effect has not actually been tested in the trials this entry could locate.
Evidence: has not been established in a controlled human sleep study; the claim is largely carried by the compound’s name and by community reports (Tier 6, community-reported information), not by the published trials.
HPA-axis modulation, the one effect with actual controlled human data
A 1994 randomised, placebo-controlled trial in normal men found that intravenous DSIP produced a significant decrease in ACTH levels compared with saline. This is the clearest positive, controlled human finding for DSIP located for this entry, though it was not the sleep effect the compound is best known for.
Evidence: has been shown in one randomised, placebo-controlled human trial (Tier 1, published human clinical evidence, single small study); not independently replicated in the sources reviewed here.
Opioid withdrawal support, tested only in an open, unblinded trial
An open (not blinded) 1998 clinical trial reported DSIP use in opioid detoxification. Without blinding or a placebo arm, this result cannot rule out expectation or natural-course effects.
Evidence: has been reported in one open human trial (Tier 2, human observational evidence without a controlled design); has not been established under blinded, placebo-controlled conditions.
What the human trials actually found
A 1993 randomised, placebo-controlled trial in eight healthy women found that intravenous DSIP, at a dose known to alter ECG patterns, did not change growth hormone or prolactin secretion, at rest or in response to an arginine challenge, and did not alter their circadian rhythm. A separate 1994 randomised, placebo-controlled trial in normal men found that DSIP produced a significant decrease in ACTH levels compared with saline, but did not change arginine-vasopressin secretion under osmotic or orthostatic stimulation.
An open trial (not blinded) reported DSIP used in opioid detoxification in the 1990s, and a 2014 Russian trial of “deltalicin” (DSIP given intranasally at 0.3 milligrams daily for two months) reported improved visual evoked potential recovery times in diabetic retinopathy patients, an outcome unrelated to sleep.
Reading across these studies, the consistent finding is not that DSIP reliably induces deep sleep in a dose-dependent, reproducible way; it is that DSIP has small, measurable, but inconsistent effects on the hypothalamic-pituitary-adrenal axis (lowering ACTH in one trial) without a clean effect on the growth-hormone or vasopressin axes, and no controlled trial located for this entry demonstrates the sleep-architecture effect that gives the compound its name in a rested, healthy human being. The lack of clean reproducibility across four decades of small trials is itself the finding.
What is not known
Whether DSIP reliably increases delta-wave sleep in humans at any dose, by any route, in a way that has been reproduced across independent groups. The controlled trials located for this entry did not demonstrate that effect cleanly.
A confirmed, endogenous physiological role for DSIP in humans. Its very existence as a distinct, functionally important endogenous peptide has been questioned in the literature since shortly after its discovery.
Modern human pharmacokinetics. The trials located for this entry are decades old and used routes and assays that would not meet current standards.
Frequently asked questions
What is DSIP?
DSIP, delta sleep-inducing peptide, is a nonapeptide first isolated from rabbit blood in 1977 during delta-wave sleep. It has never been approved as a drug anywhere.
How does DSIP work?
Its exact mechanism is not settled. It has been shown in one controlled human trial to lower ACTH, but no clean, reproduced effect on sleep architecture has been demonstrated, and its status as a distinct, functionally important endogenous peptide has been questioned in the literature.
What dosage has been studied in humans?
Controlled human trials used intravenous doses around 25 micrograms per kilogram (roughly 2 milligrams for an 80 kg adult) as a single dose. Neither trial tested a repeated or nightly dosing schedule.
What dosage commonly circulates online?
Community sleep-support material typically describes 100 to 300 micrograms nightly, by subcutaneous injection or intranasally, roughly a tenth of the per-kilogram intravenous dose used in the controlled trials and by an entirely different route.
Has DSIP been studied in humans?
Yes. Two randomised, placebo-controlled human trials from the early 1990s tested it, along with an open (unblinded) opioid-detoxification trial. None of the controlled trials measured sleep architecture as an outcome.
Is DSIP approved for use?
No. It has never been approved as a drug in any jurisdiction.
What routes of administration are reported?
The controlled human trials used intravenous administration. Community-reported use is by subcutaneous injection or intranasally.
Does DSIP actually improve sleep?
This has not been established. No controlled human trial located for this entry measured sleep architecture as an outcome, despite the compound’s name and its reputation as a sleep aid.
What side effects have been reported?
The controlled trials reviewed for this entry did not report a detailed adverse-event profile. No modern human safety or toxicology study was located.
What remains unknown about DSIP?
Whether it reliably increases delta-wave sleep in a healthy human being at any dose or route; whether it has a confirmed, functionally important endogenous role at all; and its modern human pharmacokinetics and safety profile.
Bottom line
DSIP is unusual among Russian-lineage nootropic peptides in actually having decades-old, blinded, placebo-controlled human trials. But those trials did not find the clean, reproducible deep-sleep effect its name implies; the clearest controlled finding is a modest drop in ACTH in normal men, and an unblinded opioid-detoxification trial adds only weak supporting evidence. The doses circulating online today, taken nightly by injection or intranasally, have no controlled human sleep study behind them at all. DSIP has never been approved as a drug anywhere.